Compared to clopidogrel, ticagrelor decreases the rate of all-cause mortality, vascular mortality, or myocardial infarction, without an increase in the rate of major bleeding, but with an increase in the risk of major non-CABG bleeding. [...] The benefit of clopidogrel plus aspirin in the prevention of cardiovascular events for NSTEMI-ACS patients was seen in the CURE trial, with a significant risk of major bleeding, compared to aspirin alone. [...] Dual therapy of clopidogrel and aspirin resulted in a 14% reduction in composite endpoint (cardiovascular mortality, MI or stroke), 6% reduction in all- cause mortality, 6% reduction in cardiovascular mortality, 18% reduction in MI, 18% reduction in stroke, and 26% increase in major bleeding; but the incidence of fatal bleeding and hemorrhagic stroke were not increased. [...] The reduction in the rate of non-fatal myocardial infarction was the primary driver of the primary composite endpoints in both PLATO and TRITON. [...] No statistically significant differences were detected between ticagrelor and clopidogrel on the rate of study defined major bleeding within the subgroups.29 The rate of major bleeding varied from 6.2% to 17.4% in the ticagrelor subgroups and 6.5% to 16.4% in the clopidogrel subgroups.29 For ACS patients with planned invasive management (PCI and/or CABG), no data on the rate of bleeding, or non-co
- Pages
- 31
- Published in
- Canada